8-K: Cencora Appoints Eva Boratto as New CFO

Cencora has appointed former Bath & Body Works CFO Eva C. Boratto as its new Executive Vice President and Chief Financial Officer, effective June 29, 2026.

Summary

• Eva C. Boratto appointed as Executive Vice President and Chief Financial Officer, effective June 29, 2026.
• Outgoing CFO James F. Cleary will retire and serve in an advisory capacity through the end of 2026.
• Boratto's compensation includes a $1,000,000 base salary, a 100% annual bonus target, and a $6,000,000 restricted stock unit award.
• A one-time $2,000,000 sign-on bonus was granted, subject to a one-year repayment schedule.
• Cencora reaffirmed its fiscal 2026 adjusted diluted EPS guidance of $17.70 to $17.90.
• Long-term guidance for adjusted operating income growth (7-10%) and adjusted diluted EPS growth (10-14%) remains unchanged.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as the company has secured a highly qualified successor for a critical role while maintaining stability in its financial guidance.

Positives

• Appointment of a highly experienced executive with significant healthcare and financial leadership background from CVS Health and Bath & Body Works.
• Reaffirmation of strong fiscal 2026 and long-term financial growth guidance.
• Smooth leadership transition plan with the outgoing CFO remaining in an advisory role through year-end.
• Strong track record of the incoming CFO in financial discipline and operational transformation.

Negatives

• Significant one-time cash and equity costs associated with the executive transition, including a $2 million sign-on bonus and $6 million in restricted stock units.

Risks

• Integration risks associated with new executive leadership.
• Potential for actual results to vary from forward-looking guidance due to market uncertainties.
• Reliance on non-GAAP financial measures which may not be comparable to other companies.

Future Outlook

Cencora maintains its positive growth trajectory, reaffirming its fiscal 2026 adjusted diluted EPS guidance of $17.70 to $17.90 and its long-term targets for operating income and EPS growth.

Management Comments

• Robert P. Mauch: 'Her experience leading complex, global finance organizations and a track record of financial discipline and execution make her the right finance leader for Cencora.'
• Eva C. Boratto: 'I look forward to working with Bob and the rest of the leadership team as we build on Cencora's track record of execution and growth.'

Industry Context

StockSavvy.ai notes that Cencora's move to bring in a CFO with deep healthcare and retail-transformation experience (CVS Health, Bath & Body Works) signals a strategic focus on operational efficiency and margin expansion within the competitive pharmaceutical distribution sector.

Comparison to Industry Standards

• The appointment of a seasoned healthcare-sector CFO aligns with industry standards for large-cap pharmaceutical services firms like McKesson and Cardinal Health.
• The compensation package is consistent with market benchmarks for Fortune 500 executive leadership roles.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders benefit from the continuity of financial leadership and reaffirmed guidance.
• Employees gain a leader with significant experience in large-scale organizational transformation.

Next Steps

• Eva C. Boratto to assume CFO role on June 29, 2026.
• James F. Cleary to transition to advisory role through December 31, 2026.

Key Dates

Recommendation

The filing represents a standard executive transition and a reaffirmation of existing guidance. While the appointment is positive, it does not fundamentally alter the company's current financial trajectory or risk profile, warranting a hold position for investors awaiting further operational results.

Keywords

Cencora, CFO appointment, executive leadership, financial guidance, pharmaceutical supply chain, COR